Company Overview
MiNK Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity focused on the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies designed to treat cancer and other immune-mediated diseases. This business falls within the healthcare sector and specifically the biotechnology industry, a domain characterized by high R&D expenditure and reliance on successful clinical trial outcomes to generate future revenue streams. The company currently maintains a market capitalization of $51.73M and employs 23 individuals, reflecting a small-cap organization with a lean operational structure typical of early-stage biotech firms. These financial dimensions indicate that MiNK Therapeutics is a micro-cap entity with limited revenue generation, placing it in a high-risk category where valuation is driven primarily by potential future milestones rather than current cash flows or profitability.
Financial Health
The company reports a Net Income of $-12,355,261 and an EBITDA of $-12,242,303 over the trailing twelve months, while Revenue figures are not available for this period, suggesting the business is in a pre-revenue or negligible revenue stage where operational costs significantly outweigh any generated income. The substantial gap between revenue and net income reveals a cost structure dominated by heavy research and development expenses and general administrative costs that have not yet been offset by commercial sales. Free Cash Flow stands at $-4,776,153, indicating that the company is burning cash at a significant rate, which necessitates continuous external financing to sustain operations and fund pipeline advancement. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which is consistent with a company that has not yet achieved commercial scale or where revenue is insufficient to calculate meaningful percentage margins against the high fixed costs of biotechnology. Total cash on hand is $14.28M, which contrasts with total debt of $5.73M, yet the debt-to-equity ratio is listed as N/A due to the nature of the equity position or lack of traditional equity base in this valuation phase. The current ratio is 1.08, indicating that the company possesses just enough liquid assets to cover its short-term liabilities, though the buffer is minimal and leaves little room for unexpected cash outflows. Return on Assets is -69.6%, while Return on Equity is N/A, metrics that collectively reveal the company is currently inefficient at generating profit from its asset base and lacks a traditional equity return given its loss-making status.
Valuation Assessment
The Trailing P/E Ratio is N/A because the company is unprofitable, whereas the Forward P/E is -3.05 and the Price to Book ratio is -3.75, creating a valuation profile that defies standard multiple analysis for profitable firms and instead reflects market pricing based on asset liquidation value or option value. The negative forward P/E and negative price-to-book ratio imply that the market is not valuing the stock based on current earnings power or book value multiples, which is common for clinical-stage biotechs where intrinsic value is tied to intellectual property and pipeline potential rather than historical financials. The Price to Sales ratio is N/A, reinforcing that revenue generation is not yet a primary driver of valuation, while the EV/EBITDA stands at -3.53, further highlighting the disconnect between traditional valuation metrics and the company's current financial reality. The stock has a 52-Week High of $76.00 and a 52-Week Low of $6.34, and without a specific current price provided in the source facts, the range indicates extreme volatility and a wide dispersion of market sentiment regarding the company's future prospects. The Beta is 0.35, which suggests that the stock's price volatility is significantly lower than the broader market, a characteristic often seen in small-cap biotechnology stocks that may be priced to trade independently of general market swings due to their specific niche focus.
Growth & Income
Revenue Growth and Earnings Growth rates are both listed as N/A, as the company has not yet produced sufficient revenue to calculate year-over-year growth percentages. Because the company is not generating significant profits, it cannot pay dividends; consequently, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the company reinvests all available resources, including its cash reserves, directly into research, development, and clinical trials to advance its iNKT cell therapy pipeline. The absence of a dividend yield confirms that the investment vehicle is purely growth-oriented, relying on capital appreciation rather than income distribution to provide returns to shareholders. The overall growth and income profile is defined by a complete reliance on future commercialization success, as the company currently offers no current income yield and its growth potential is contingent upon the successful development and regulatory approval of its therapeutic candidates.